Neonatal outcomes after late-gestation exposure to selective serotonin reuptake inhibitors

Journal of Clinical Psychopharmacology

Volumn 32, Issue 5, 2012, Pages 615-621

  Grzeskowiak, Luke E ^a   Gilbert, Andrew L ^a   Morrison, Janna L ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

depression; low birth weight; neonatal outcomes; pregnancy; preterm birth; serotonin reuptake inhibitor

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HOSPITALIZATION; HUMAN; LENGTH OF STAY; LIFESTYLE; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; MENTAL DISEASE; OUTCOME ASSESSMENT; PREGNANCY OUTCOME; PREMATURE LABOR; PRENATAL DRUG EXPOSURE; PRENATAL GROWTH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SMALL FOR DATE INFANT;

ADULT; COHORT STUDIES; FEMALE; HOSPITALIZATION; HUMANS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; LENGTH OF STAY; MENTAL DISORDERS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PRENATAL EXPOSURE DELAYED EFFECTS; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; SOUTH AUSTRALIA; YOUNG ADULT;

EID: 84865860674     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31826686bc     Document Type: Article

References (56)

1. Hallberg P, Sjoblom V. The use of selective serotonin reuptake inhibitors during pregnancy and breast-feeding: a review and clinical aspects. J Clin Psychopharmacol. 2005;25:59-73.
2. Ellfolk M, Malm H. Risks associated with in utero and lactation exposure to selective serotonin reuptake inhibitors (SSRIs). Reprod Toxicol. 2010;30:249-260.
3. Sugiura-Ogasawara M, Furukawa TA, Nakano Y, et al. Depression as a potential causal factor in subsequent miscarriage in recurrent spontaneous aborters. Hum Reprod. 2002;17:2580-2584.
4. Nakhai-Pour HR, Broy P, Berard A. Use of antidepressants during pregnancy and the risk of spontaneous abortion. CMAJ. 2010;182:1031-1037.
5. Dayan J, Creveuil C, Herlicoviez M, et al. Role of anxiety and depression in the onset of spontaneous preterm labor. Am J Epidemiol. 2002;155:293-301.
6. Dayan J, Creveuil C, Marks MN, et al. Prenatal depression, prenatal anxiety, and spontaneous preterm birth: a prospective cohort study among women with early and regular care. Psychosom Med. 2006;68:938-946.
7. Orr ST, James SA, Blackmore Prince C. Maternal prenatal depressive symptoms and spontaneous preterm births among African-American women in Baltimore, Maryland. Am J Epidemiol. 2002;156:797-802.
8. Steer RA, Scholl TO, Hediger ML, et al. Self-reported depression and negative pregnancy outcomes. J Clin Epidemiol. 1992;45:1093-1099.
9. Oberlander TF, Warburton W, Misri S, et al. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry. 2006;63:898-906.
10. Paarlberg KM, Vingerhoets AD, Passchier J, et al. Psychosocial factors and pregnancy outcome: A review with emphasis on methodological issues. J Psychosom Res. 1995;39:563-595.
11. Preti A, Cardascia L, Zen T, et al. Obstetric complications in patients with depressionVa population-based caseYcontrol study. J Affect Disord. 2000;61:101-106.
12. McAnarney ER, Stevens-Simon C. Maternal psychological stress/depression and low birth weight: is there a relationship? Arch Pediatr Adolesc Med. 1990;144:789-792.
13. Field T, Diego M, Dieter J, et al. Prenatal depression effects on the fetus and the newborn. Infant Behav Dev. 2004;27:216-229.
14. Hoffman S, Hatch MC. Depressive symptomatology during pregnancy: evidence for an association with decreased fetal growth in pregnancies of lower social class women. Health Psychol. 2000;19:535-543.
15. Chung TKH, Lau TK, Yip ASK, et al. Antepartum depressive symptomatology is associated with adverse obstetric and neonatal outcomes. Psychosom Med. 2001;63:830-834.
16. Lund N, Pedersen LH, Henriksen TB. Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes. Arch Pediatr Adolesc Med. 2009;163:949-954.
17. Oberlander TF, Warburton W, Misri S, et al. Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: population-based study. Br J Psychiatry. 2008;192:338-343.
18. Wisner KL, Sit DKY, Hanusa BH, et al. Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am J Psychiatry. 2009;166:557-566.
19. Suri R, Altshuler L, Hendrick V, et al. The impact of depression and fluoxetine treatment on obstetrical outcome. Arch Womens Ment Health. 2004;7:193-200.
20. Slattery MM, Morrison JJ. Preterm delivery. Lancet. 2002;360:1489-1497.
21. Davis RL, Rubanowice D, McPhillips H, et al. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiol Drug Saf. 2007;16:1086-1094.
22. Costei AM, Kozer E, Ho T, et al. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med. 2002;156:1129-1132.
23. Chambers CD, Johnson KA, Dick LM, et al. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med. 1996;335:1010-1015.
24. Wen SW, Yang Q, Garner P, et al. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Ostet Gynecol. 2006;194:961-966.
25. Kallen B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med. 2004;158:312-316.
26. Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antidepressant exposure. Am J Psychiatry. 2002;159:2055-2061.
27. Maschi S, Clavenna A, Campi R, et al. Neonatal outcome following pregnancy exposure to antidepressants: a prospective controlled cohort study. BJOG. 2008;115:283-289.
28. Reis M, Källén B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med. 2010;40:1723-1733.
29. Diav-Citrin O, Shechtman S, Weinbaum D, et al. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Br J Clin Pharmacol. 2008;66:695-705.
30. Casper RC, Fleisher BE, Lee-Ancajas JC, et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr. 2003;142:402-408.
31. Pastuszak A, Schick-Boschetto B, Zuber C, et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA. 1993;269:2246-2248.
32. Ferreira E, Carceller AM, Agogue C, et al. Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates. Pediatrics. 2007;119:52-59.
33. Toh S, Mitchell AA, Louik C, et al. Antidepressant use during pregnancy and the risk of preterm delivery and fetal growth restriction. J Clin Psychopharmacol. 2009;29: 555-560.
34. Sivojelezova A, Shuhaiber S, Sarkissian L, et al. Citalopram use in pregnancy: prospective comparative evaluation of pregnancy and fetal outcome. Am J Ostet Gynecol. 2005;193:2004-2009.
35. Goldenberg RL, Culhane JF. Low birth weight in the United States. Am J Clin Nutr. 2007;85:584SY590S.
36. Lewis AJ, Galbally M, Opie G, et al. Neonatal growth outcomes at birth and one month postpartum following in utero exposure to antidepressant medication. Aust N Z J Psychiatry. 2010;44:482-487.
37. Nulman I, Rovet J, Stewart DE, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med. 1997;336:258-262.
38. Nulman I, Rovet J, Stewart DE, et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry. 2002;159:1889-1895.
39. Zeskind PS, Stephens LE. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics. 2004;113:368-375.
40. Kulin NA, Pastuszak A, Sage SR, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA. 1998;279:609-610.
41. Malm H, Klaukka T, Neuvonen PJ. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol. 2005;106:1289-1296.
42. Colvin L, Slack Smith L, Stanley FJ, et al. Dispensing patterns and pregnancy outcomes for women dispensed selective serotonin reuptake inhibitors in pregnancy. Birth Defects Res A Clin Mol Teratol. 2011;91:142-152.
43. Hendrick V, Smith LM, Suri R, et al. Birth outcomes after prenatal exposure to antidepressant medication. Am J Obstet Gynecol. 2003;188:812-815.
44. Cohen LS, Heller VL, Bailey JW, et al. Birth outcomes following prenatal exposure to fluoxetine. Biol Psychiatry. 2000;48:996-1000.
45. Levinson-Castiel R, Merlob P, Linder N, et al. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med. 2006;160:173-176.
46. Galbally M, Lewis AJ, Lum J, et al. Serotonin discontinuation syndrome following in utero exposure to antidepressant medication: prospective controlled study. Aust N Z J Psychiatry. 2009;43:846-854.
47. Moses-Kolko EL, Bogen D, Perel J, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors literature review and implications for clinical applications. JAMA. 2005;293:2372-2383.
48. Sanz EJ, De-las-Cuevas C, Kiuru A, et al. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet. 2005;365:482-487.
49. Laine K, Heikkinen T, Ekblad U, et al. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry. 2003;60:720-726.
50. Grzeskowiak LE, Gilbert AL, Morrison JL. Hospital pharmacy dispensing records for pharmacoepidemiology research into late gestation exposure to antidepressants. J Pharm Pract Res. 2010;40:265-268.
51. South Australian Pregnancy Record. Available at: http://www.health.sa. gov.au/pehs/pregnancy-record.htm. Accessed July 7, 2011.
52. McLean A, Scott J, Keane R, et al. Validation of the 1994 South Australian Perinatal Data Collection Form. Adelaide, South Australia: Pregnancy Outcome Unit, Epidemiology Branch, Dept. of Human Services; 2001.
53. Blair EM, Liu Y, De Klerk NH, et al. Optimal fetal growth for the Caucasian singleton and assessment of appropriateness of fetal growth: an analysis of a total population perinatal database [online]. BMC Pediatr. 2005;5:13.
54. Australian Bureau of Statistics. Socio-Economic Indexes for Areas (SEIFA) V Technical Paper. Report no. 2039.0.55.001. Canberra, Australia: AustralianBureau of Statistics; 2008.
55. Bakker MK, Kolling P, van den Berg PB, et al. Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands. Br J Clin Pharmacol. 2008;65:600-606.
56. Alwan S, Reefhuis J, Rasmussen SA, et al. Patterns of antidepressant medication use among pregnant women in a United States population. J Clin Pharmacol. 2011;51:264-270.